IDERA PHARMACEUTICALS INC (IDRA) Stock Price & Overview
NASDAQ:IDRA • US45168K4058
Current stock price
The current stock price of IDRA is 0.425 USD. Today IDRA is down by -21.57%. In the past month the price increased by 54.55%. In the past year, price decreased by -28.08%.
IDRA Key Statistics
- Market Cap
- 25.083M
- P/E
- 0.18
- Fwd P/E
- N/A
- EPS (TTM)
- 2.34
- Dividend Yield
- N/A
IDRA Stock Performance
IDRA Stock Chart
IDRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IDRA. When comparing the yearly performance of all stocks, IDRA is a bad performer in the overall market: 74.57% of all stocks are doing better.
IDRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IDRA. Both the profitability and financial health of IDRA have multiple concerns.
IDRA Earnings
IDRA Forecast & Estimates
IDRA Groups
Sector & Classification
IDRA Financial Highlights
Over the last trailing twelve months IDRA reported a non-GAAP Earnings per Share(EPS) of 2.34. The EPS increased by 160.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
IDRA Ownership
IDRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IDRA
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
Company Info
IPO: 1996-01-25
IDERA PHARMACEUTICALS INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA 19341 US
CEO: Vincent J. Milano
Employees: 13
Phone: 14843481600.0
IDERA PHARMACEUTICALS INC / IDRA FAQ
What does IDRA do?
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
What is the stock price of IDERA PHARMACEUTICALS INC today?
The current stock price of IDRA is 0.425 USD. The price decreased by -21.57% in the last trading session.
Does IDERA PHARMACEUTICALS INC pay dividends?
IDRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IDRA stock?
IDRA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does IDERA PHARMACEUTICALS INC (IDRA) report earnings?
IDERA PHARMACEUTICALS INC (IDRA) will report earnings on 2023-03-29.
Who owns IDERA PHARMACEUTICALS INC?
You can find the ownership structure of IDERA PHARMACEUTICALS INC (IDRA) on the Ownership tab.